Infinity Pharmaceuticals (OTCPK:INFI.Q) - Aandelenkoers, Nieuws & Analyse

INFI.Q Overzicht aandelen

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. Meer informatie

INFI.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 14.5% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $90 )

Negatief eigen vermogen

Heeft minder dan 1 jaar cash runway

+ 3 meer risico's

Infinity Pharmaceuticals, Inc. Concurrenten

Mymetics

OTCPK:MYMX

US$151.0

DermTech

OTCPK:DMTK.Q

US$35.0

Aridis Pharmaceuticals

OTCPK:ARDS

US$53.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Infinity Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$0.000001
52 Week Hoogtepunt	US$0.26
52 Week Laag	US$0.000001
Bèta	1.33
11 maand verandering	-99.00%
3 maanden verandering	-99.96%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Rendement voor aandeelhouders

	INFI.Q	US Biotechs	US Markt
7D	0%	4.0%	2.0%
1Y	-100.0%	18.0%	32.4%

Rendement versus industrie: INFI.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18 % opleverde.

Rendement versus markt: INFI.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is INFI.Q's price volatile compared to industry and market?
INFI.Q volatility
INFI.Q Average Weekly Movement	188.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van INFI.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van INFI.Q is het afgelopen jaar gestegen van 89% naar 189%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	30	Seth Tasker	www.infi.com

Infinity Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Infinity Pharmaceuticals zich tot de beurswaarde?
INFI.Q fundamentele statistieken
Marktkapitalisatie	US$90.00
Inkomsten(TTM)	-US$40.95m
Inkomsten(TTM)	US$2.57m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is INFI.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
INFI.Q resultatenrekening (TTM)
Inkomsten	US$2.57m
Kosten van inkomsten	US$28.53m
Brutowinst	-US$25.96m
Overige uitgaven	US$14.99m
Inkomsten	-US$40.95m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.45
Brutomarge	-1,010.35%
Nettowinstmarge	-1,593.93%
Schuld/Eigen Vermogen Verhouding	-127.9%

Hoe presteerde INFI.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

INFI.Q Overzicht aandelen

Risicoanalyse

Infinity Pharmaceuticals, Inc. Concurrenten

OTCPK:MYMX

US$151.0

OTCPK:DMTK.Q

US$35.0

OTCPK:ARDS

US$53.0

OTCPK:GNCA.Q

US$5.9k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 20% to US$4.00

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Consensus revenue estimates increase by 276%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Consensus estimates of losses per share improve by 10%

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 20%

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.67

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Consensus revenue estimates increase by 232%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$9.00

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Price target increased to US$9.71

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Investigating Infinity Pharmaceuticals

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Consensus revenue estimates increase to US$1.89m

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Consensus forecasts updated

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: US$5.36

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

New 90-day high: US$2.80